Elekta AB (publ) (OTCMKTS:EKTAY) Given Average Recommendation of “Reduce” by Brokerages

Shares of Elekta AB (publ) (OTCMKTS:EKTAY) have earned an average rating of “Reduce” from the seven analysts that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company.

Separately, Barclays started coverage on Elekta AB (publ) in a research report on Thursday, October 5th. They set an “underweight” rating on the stock.

Elekta AB (publ) Trading Up 0.4 %

Shares of EKTAY stock opened at $8.29 on Tuesday. The firm has a market capitalization of $3.18 billion, a P/E ratio of 29.61 and a beta of 1.10. Elekta AB has a twelve month low of $5.52 and a twelve month high of $8.65. The company has a quick ratio of 0.83, a current ratio of 1.12 and a debt-to-equity ratio of 0.57. The stock’s fifty day simple moving average is $7.02 and its 200 day simple moving average is $7.46.

Elekta AB (publ) (OTCMKTS:EKTAY) last issued its quarterly earnings data on Thursday, August 24th. The company reported $0.06 earnings per share for the quarter. The business had revenue of $361.42 million for the quarter. Elekta AB (publ) had a return on equity of 14.15% and a net margin of 6.49%. As a group, sell-side analysts predict that Elekta AB will post 0.32 EPS for the current fiscal year.

Elekta AB (publ) Company Profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.